Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2018.11.10
- Author:
Xuefeng LENG
1
;
Jiandong MEI
1
;
Lunxu LIU
1
Author Information
1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor;
Lung neoplasms;
Programmed death ligand 1;
Signaling pathways
- MeSH:
Adenocarcinoma of Lung;
genetics;
pathology;
B7-H1 Antigen;
metabolism;
ErbB Receptors;
genetics;
Gene Expression Regulation, Neoplastic;
Humans;
Mutation;
Signal Transduction;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(11):875-879
- CountryChina
- Language:Chinese
-
Abstract:
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors were landmarks in the treatment of non-small cell lung cancer (NSCLC). However, the regulation mechanisms of PD-L1 expression were not fully clear in NSCLC patients with EGFR mutations. Multiple signaling pathways may be involved in the tumorigenesis regulation. This paper summarized and reviewed the potential EGFR mutations impacting on PD-L1 expression with aims to the development of strategies on immunochemical therapy for NSCLC.
.
